达英-35对多囊卵巢综合征患者糖脂代谢的影响

doi:10.3969/j.issn.1006-7795.2016.04.003

首都医科大学学报 ›› 2016, Vol. 37 ›› Issue (4): 424-430.doi: 10.3969/j.issn.1006-7795.2016.04.003

达英-35对多囊卵巢综合征患者糖脂代谢的影响

李扬璐¹, 阮祥燕^1,2, 赵越¹, 杜娟¹, 王利娟¹, 崔亚美¹, Alfred O. Mueck^1,2

1. 首都医科大学附属北京妇产医院内分泌科, 北京 100026;
2. 德国图宾根大学妇产医院绝经内分泌中心, 图宾根 D-72076, 德国

收稿日期:2016-06-15 出版日期:2016-08-21 发布日期:2016-07-18
通讯作者: 阮祥燕 E-mail:ruanxiangyan@163.com
基金资助:
北京市自然科学基金（Y161011），北京市卫生系统高层次卫生技术人才（2014-2-016），国家外国专家局2016年度北京市引进国外技术、管理人才项目（高外端）（20161100031），首都医科大学附属北京妇产医院，北京妇幼保健院学科带头人项目（2013-1）。

Effects of Diane-35 on the glucose and lipid metabolism in patients with polycystic ovary syndrome

Li Yanglu¹, Ruan Xiangyan^1,2, Zhao Yue¹, Du Juan¹, Wang Lijuan¹, Cui Yamei¹, Alfred O. Mueck^1,2

1. Department of Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China;
2. Section of Endocrinology and Menopause, Department of Women's Health, University of Tubingen, Tubingen D-72076, Germany

Received:2016-06-15 Online:2016-08-21 Published:2016-07-18
Supported by:
This study was supported by Natural Science Foundation Beijing(Y161011);Beijing Municipality Health Technology High-level Talent(2014-2-016);Foreign Technical and Administrative Talent Introduction Project in 2016,State Administration of Foreign Experts Affairs,the P. R. of China(20161100031);Project of Discipline Leader,Beijing Obstetrics and Gynecology Hospital,Capital Medical University,Beijing Maternal and Child Health Care Hospital(2013-1).

摘要/Abstract

摘要： 目的观察达英-35治疗多囊卵巢综合征（polycystic ovary syndrome，PCOS）的疗效，探讨其对PCOS患者激素及糖脂代谢的影响。方法将确诊为PCOS的100名患者按照国际糖尿病联盟对代谢综合征的诊断分为代谢综合征（metabolic syndrome，MS）组和非代谢综合征组（non-MS）。观察并比较两组采用达英-35治疗3个月前后的激素、糖脂代谢指标的变化。结果治疗后MS组体质量指数显著降低，非MS组无明显改变；两组血清睾酮和黄体生成素（luteinizing hormone，LH）/测量卵泡刺激素（follicle stimulating hormone，FSH）明显下降（P<0.05）；MS组总胆固醇降低，非MS组显著升高，两组间变化幅度比较，差异近似有统计学意义（P=0.054）；两组三酰甘油浓度均有显著升高，MS组升高幅度较大，组间差异有统计学意义（P<0.05）；MS组高密度脂蛋白胆固醇（high density lipoprotein-cholesterol，HDL-C）在治疗后略有上升，而非MS组显著升高，组间比较差异无统计学意义（P<0.05）；MS组LDL-C均有轻度下降，非MS组则略有上升，组间比较差异有统计学意义（P<0.05）。MS组空腹血糖显著下降，非MS组显著上升，组间比较差异有统计学意义（P<0.05）。MS组空腹胰岛素轻度下降，非MS组轻度上升，组间比较差异无统计学意义（P>0.05）。结论达英-35能够调整月经周期，改善高雄激素状态，并不恶化PCOS的糖脂代谢。在治疗过程中，除药物治疗外，还应注意配合饮食控制和运动，以期达到更好的疗效。

关键词: 多囊卵巢综合征, 代谢综合征, 达英-35, 糖脂代谢

Abstract: Objective To observe the effects of Diane-35 on polycystic ovary syndrome (PCOS), and to investigate its influence on hormone, glucose and lipid metabolism in PCOS patients. Methods Totally 100 patients diagnosed as PCOS were divided into two groups, metabolic syndrome (MS) group (n=64) and non-MS group (n=36), according to the MS criteria formulated by International Diabetes Federation (IDF). Hormone level and parameters of glucose and lipid metabolism were detected and compared between the two groups before and after treatment by Diane-35 for 3 months. Results The body mass index decreased significantly after treatment in MS group, while no obvious change in non-MS group. The serum testosterone and LH/FSH decreased in both groups (P<0.05). The total cholesterol in MS group slightly decreased, but increased significantly in non-MS group. The triglyceride in both groups increased significantly, especially in MS group, and the difference between the groups was statistically significant. HDL-C increased in both group, but only increased significantly in non-MS group (P<0.05). LDL-C decreased in MS group and increased in non-MS group without statistical difference, but the difference of between the groups was statistically significant. Fasting glucose decreased in MS group and increased in non-MS group significantly, and the difference between the groups was statistically significant. Fasting insulin decreased in MS group and increased in non-MS group without significant difference, and the difference between the groups was not significant. Conclusion Diane-35 can modify the menstrual cycle, and improve the hyperandrogenism such as hirsutism and acne, and do not deteriorate the glucose and lipid metabolism. PCOS treatment should combine diane-35 with diet and exercise, helping PCOS patients achieving the best effect.

Key words: polycystic ovary syndrome, metabolic syndrome, Diane-35, glucose and lipid metabolism

中图分类号:

R711.75

李扬璐, 阮祥燕, 赵越, 杜娟, 王利娟, 崔亚美, Alfred O. Mueck. 达英-35对多囊卵巢综合征患者糖脂代谢的影响[J]. 首都医科大学学报, 2016, 37(4): 424-430.

Li Yanglu, Ruan Xiangyan, Zhao Yue, Du Juan, Wang Lijuan, Cui Yamei, Alfred O. Mueck. Effects of Diane-35 on the glucose and lipid metabolism in patients with polycystic ovary syndrome[J]. Journal of Capital Medical University, 2016, 37(4): 424-430.

参考文献

[1] Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome(PCOS)[J]. Hum Reprod, 2004, 19(1): 41-47.
[2] Alberti K G, Zimmet P, Shaw J. et al. The metabolic syndrome-a new worldwide definition[J]. Lancet, 2005, 366(9491): 1059-1062.
[3] Alberti KGMM, Eckel R H, Grundy S M, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity[J]. Circulation, 2009, 120(16): 1640-1645.
[4] Bil E, Dilbaz B, Cirik D A. Metabolic syndrome and metabolic risk profile according to polycystic ovary syndrome phenotype[J]. J Obstet Gynaecol Res, 2016,42(7):837-843.
[5] Kelly C C, Lyall H, Petrie JR, e t al. Low grade chronic inflammation in women with polycystic ovarian syndrome[J]. J Clin Endocrinol Metab, 2001,86(6):2453-2435.
[6] Gallo M F, Lopez L M, Grimes D A, et al. Combination contraceptives: effects on weight[J]. Cochrane Database Syst Rev, 2014, 29(1):CD003987.
[7] Orbetsova M, Kamenov Z, Kolarov G, et al. Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy[J]. Akush Gimekol: sotilia, 2006,45(7):16-28.
[8] Wu H, Ruan X, Jin J, et al. Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes[J]. Gynecol Endocrinol, 2015, 31(7):548-551.
[9] Trikudanathan S. Polycystic ovarian syndrome[J]. Med Clin North Am, 2015, 99(1):221-235.
[10] Hsu M I, Liou T H, Liang S J, et al. Inappropriate gonadotropin secretion in polycystic ovary syndrome[J]. Fertil Steril, 2009, 91(4):1168-1174.
[11] 马从顺,林芸,张春晖,等. 血清黄体生成素与卵泡刺激素比值对卵巢多囊样改变患者确诊多囊卵巢综合征的价值[J]. 中华妇产科杂志, 2011, 49(3): 177-181.
[12] Wu J, Zhu Y, Jiang Y, et al. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome[J]. Gynecol Endocrinol, 2008, 24(7):392-398.
[13] 陈雪梅. 不同药物预处理多囊卵巢综合征并不孕患者的疗效及副反应分析[J]. 实用医学杂志, 2011,27 (15): 2830-2832.
[14] Ehrmann D A. Polycystic ovary syndrome[J]. N Engl J Med, 2005, 352(12):1223-1236.
[15] Cagnacci A, Paoletti A M, Renzi A, et al. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel[J]. J Clin Endocrinol Metab, 2003,88(8):3621-3625.
[16] Vrbíková J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome[J]. Hum Reprod Update, 2005,11(3):277-291.
[17] Halperin I J, Kumar S S, Stroup D F. The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies[J]. Hum Reprod, 2011, 26(1):191-201.
[18] Karabulut A, Demirlenk S, Sevket O. Effects of ethinyl estradiol-cyproterone acetate treatment on metabolic syndrome, fat distribution and carotid intima media thickness in polycystic ovary syndrome[J]. Gynecol Endocrinol, 2012,28(4):245-248.
[19] Jing Z, Liang-Zhi X, Tai-Xiang W, et al. The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: An updated systematic review[J]. Gynecol Endocrinol, 2008, 24(10):590-600.
[20] 武红琴,阮祥燕,卢永军,等. 综合管理下达英-35与达英-35联合二甲双胍治疗多囊卵巢综合征的疗效研究[J]. 首都医科大学学报, 2014,35(4):407-413.
[21] 卢永军,阮祥燕,田玄玄,等. 多囊卵巢综合征综合治疗疗效的评价[J]. 首都医科大学学报,2013,34(4):525-529.
[22] 杨颖,王金敏,彭书苹,等. 肥胖型多囊卵巢综合征患者临床特征分析[J]. 中国煤炭工业医学杂志, 2014,17(9) :1453-1455.

达英-35对多囊卵巢综合征患者糖脂代谢的影响

Effects of Diane-35 on the glucose and lipid metabolism in patients with polycystic ovary syndrome

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	苏志燕, 刘薇, 史婷婷. 老年2型糖尿病患者血尿酸浓度与代谢综合征的相关性分析[J]. 首都医科大学学报, 2023, 44(1): 137-142.
[2]	李健, 白文佩, 江波, 白栎然, 吴凤云. 生酮饮食对超重/肥胖多囊卵巢综合征女性月经及生育力的影响[J]. 首都医科大学学报, 2021, 42(6): 1021-1025.
[3]	王虎生, 阮祥燕, 程姣姣, Alfred O. Mueck. 肥胖型多囊卵巢综合征的氧化应激与脂代谢关系的研究[J]. 首都医科大学学报, 2021, 42(4): 540-546.
[4]	杨瑜, 阮祥燕, 鞠蕊, 许新, 谷牧青, 程姣姣. 屈螺酮炔雌醇Ⅱ对多囊卵巢综合征患者血清抗苗勒管激素的影响[J]. 首都医科大学学报, 2021, 42(4): 547-552.
[5]	刘真, 殷冬梅, 战思恩, 阮祥燕. 黄连素改善多囊卵巢综合征患者代谢异常的系统评价[J]. 首都医科大学学报, 2021, 42(4): 588-595.
[6]	来璇, 张爱华. 代谢综合征对慢性肾脏病患者生存预后的影响[J]. 首都医科大学学报, 2021, 42(4): 609-614.
[7]	王景尚, 尹晓丹, 何军琴, 武颖, 张莹, 李宪锐. 来曲唑联合高糖高脂饮食构建多囊卵巢综合征伴胰岛素抵抗大鼠模型研究[J]. 首都医科大学学报, 2021, 42(3): 436-442.
[8]	张黎锐, 郑薇, 刘程, 梁馨, 张莉, 田志红, 李光辉. 多囊卵巢综合征孕妇妊娠期增重模式与母儿结局的关系[J]. 首都医科大学学报, 2021, 42(2): 169-176.
[9]	张露平, 阮祥燕, 鞠蕊, 秦爽, 王宾红, 许新, 杨瑜, Alfred O. Mueck. 围绝经期及绝经后女性基于腰椎定量电子计算机断层扫描测定的内脏脂肪与糖脂代谢的相关性[J]. 首都医科大学学报, 2020, 41(4): 508-513.
[10]	闵敏, 阮祥燕, 王虎生, 程姣姣, 罗穗豫, 许仲婷, 李萌, Alfred O. Mueck. 奥利司他综合干预对超重或肥胖型多囊卵巢综合征患者代谢综合征及其组分的影响[J]. 首都医科大学学报, 2020, 41(4): 514-519.
[11]	王宾红, 阮祥燕, 鞠蕊, 豆竹丽, 秦爽, 张露平, 许新, 杨瑜, Alfred O. Mueck. 综合干预治疗对多囊卵巢综合征患者雄激素浓度的影响[J]. 首都医科大学学报, 2020, 41(4): 520-524.
[12]	豆竹丽, 阮祥燕, 鞠蕊, 王宾红, 秦爽, 许新, 杨瑜, 张露平. 综合干预后多囊卵巢综合征不孕患者应用来曲唑促排卵的临床效果[J]. 首都医科大学学报, 2020, 41(4): 525-529.
[13]	秦爽, 阮祥燕, 王宾红, 鞠蕊, 张露平, 豆竹丽, 程姣姣, 金婧. 多囊卵巢综合征患者促排卵周期中成熟卵泡性激素浓度对妊娠的影响[J]. 首都医科大学学报, 2020, 41(4): 530-535.
[14]	王延雪, 胡虹英, 李新刚, 鹿星梦, 郜桂菊, 梁洪远, 肖江, 杨涤, 王芳, 韩晓涛. 初治人类免疫缺陷病毒感染者合并代谢综合征及心血管病风险状况及其临床特点分析[J]. 首都医科大学学报, 2020, 41(1): 40-44.
[15]	修双玲, 穆志静, 孙丽娜, 赵蕾, 韩青, 曹雪霞. 老年2型糖尿病代谢综合征患者骨质疏松危险因素研究[J]. 首都医科大学学报, 2020, 41(1): 108-112.